Peter Bou Dib: Understanding von Willebrand Factor in Bleeding and Thrombotic Disorders
Peter Bou Dib, Key Account Manager at Sino Biological Europe, shared a post on LinkedIn about a recent article by François Depasse et al, published in Expert Review of Hematology:
”Understanding Von Willebrand Factor (VWF): Key to Diagnosing Bleeding and Thrombotic Disorders
Von Willebrand factor is essential for blood clotting and vascular integrity.
Defects in VWF cause the most common inherited bleeding disorder—von Willebrand disease (VWD)—and also play a role in acquired bleeding syndromes and thrombotic conditions.
Key Insights:
- VWD diagnosis relies on a panel of specialized lab tests measuring VWF antigen and activity, factor VIII, and multimer analysis.
- VWF levels vary with age, pregnancy, blood group, inflammation, and other clinical factors.
- Acquired von Willebrand syndrome occurs in settings like cardiovascular disease, hematological malignancies, and autoimmune disorders.
- VWF is involved in thrombotic microangiopathies linked to ADAMTS13 dysfunction.
- Genetic testing complements phenotypic assays, especially for complex cases.”
Title: Von Willebrand factor is a multifaceted player in hemostasis requiring a diverse array of analytical and diagnostic approaches
Authors: François Depasse, Nikolaus B. Binder, Mariona Bono, Matthias Germer, Michael Heins, Martina Leplatoni, Jürgen Patzke, Stephan Schwers, Michael Spannagl, Peter L. Turecek
Read the Full Article on Expert Review of Hematology
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 6, 2026, 15:30Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 3
-
Apr 6, 2026, 15:19Ifeanyichukwu Ifechidere: When PT and APTT Are Normal but Bleeding Persists
-
Apr 6, 2026, 14:59Michal Farkowski: Cardiooncology Also Deals with Arrhythmia
-
Apr 6, 2026, 14:08David McIntosh: What Truly Determines the Safety of Plasma Donation
-
Apr 6, 2026, 13:52Andrew Zapfel: Expanding Newborn Screening for Sickle Cell Disease in Africa
-
Apr 6, 2026, 13:51Frank Nocken: FDA Approves Caplacizumab Therapy for Pediatric Acquired TTP
-
Apr 6, 2026, 13:45Svenja Tatjana Barckhausen: From Plasma Dependence to Self-Sufficiency in Africa
-
Apr 6, 2026, 13:35Gregory Piazza: When Antibodies Trigger Thrombosis
-
Apr 6, 2026, 13:24Paritosh Garg: Importance of Ruling Out an Underlying Cause Before Treatment of AIHA